NEW YORK (GenomeWeb) – MGI, a subsidiary of BGI, has received the medical device registration certificate from the China Food and Drug Administration for its two next-generation sequencers, MGISEQ-2000 and MGISEQ-200. The certification enables healthcare organizations to use the instruments for clinical purposes.
According to the company, the MGISEQ-2000 instrument has two different flow cells that enable users to combine different operating modes and can generate 1,080 gigabases of sequencing data within 48 hours. MGISEQ-200 can produce 60 gigabases of data in less than 48 hours.
MGI launched the instruments last year.